Hammad Asmaa S A, Sayed-Ahmed Mohamed M, Abdel Hafez Sara Mohamed Naguib, Ibrahim Ahmed R N, Khalifa Mohamed M A, El-Daly Mahmoud
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Minia University, Minia, 61511, Egypt.
Pharmacology and Experimental Oncology Unit, National Cancer Institute, Cairo University, Cairo, 11796, Egypt.
Chem Biol Interact. 2023 May 1;376:110446. doi: 10.1016/j.cbi.2023.110446. Epub 2023 Mar 9.
Chemotherapy-induced peripheral neuropathy is a common adverse effect associated with a number of chemotherapeutic agents including paclitaxel (PTX) which is used in a wide range of solid tumors. Development of PTX-induced peripheral neuropathy (PIPN) during cancer treatment requires dose reduction which limits its clinical benefits. This study is conducted to investigate the role of toll like receptor-4 (TLR4) /p38 signaling and Klotho protein expression in PIPN and the role of trimetazidine (TMZ) in this pathway. Sixty-four male Swiss albino mice were divided into 4 groups (n = 16); Group (1) injected intraperitoneally (IP) with ethanol/tween 80/saline for 8 successive days. Group (2) received TMZ (5 mg/kg, IP, day) for 8 successive days. Group (3) treated with 4 doses of PTX (4.5 mg/kg, IP) every other day over a period of 7 days. Group (4) received a combination of TMZ as group 2 and PTX as group 3. The Effect of TMZ on the antitumor activity of PTX was studied in another set of solid Ehrlich carcinoma (SEC)-bearing mice that was similarly divided as the above-mentioned set. TMZ mitigated tactile allodynia, thermal hypoalgesia, numbness and fine motor discoordination associated with PTX in Swiss mice. The results of the current study show that the neuroprotective effect of TMZ can be attributed to inhibition of TLR4/p38 signaling which also includes a reduction in matrix metalloproteinase-9 (MMP9) protein levels as well as the proinflammatory interleukin-1β (IL-1β) and preserving the levels of the anti-inflammatory IL-10. Moreover, the current study is the first to demonstrate that PTX reduces the neuronal levels of klotho protein and showed its modulation via cotreatment with TMZ. In addition, this study showed that TMZ neither alter the growth of SEC nor the antitumor activity of PTX. In conclusion, we suggest that (1) Inhibition of Klotho protein and upregulation of TLR4/p38 signals in nerve tissues may contribute to PIPN. (2) TMZ attenuates PIPN by modulating TLR4/p38 and Klotho protein expression without interfering with its antitumor activity.
化疗引起的周围神经病变是多种化疗药物常见的不良反应,包括用于多种实体瘤治疗的紫杉醇(PTX)。癌症治疗期间发生的PTX诱导的周围神经病变(PIPN)需要降低剂量,这限制了其临床疗效。本研究旨在探讨Toll样受体4(TLR4)/p38信号通路及Klotho蛋白表达在PIPN中的作用,以及曲美他嗪(TMZ)在此通路中的作用。将64只雄性瑞士白化小鼠分为4组(每组n = 16);第1组连续8天腹腔注射乙醇/吐温80/生理盐水;第2组连续8天接受TMZ(5 mg/kg,腹腔注射,每日一次);第3组在7天内每隔一天接受4剂PTX(4.5 mg/kg,腹腔注射);第4组同时接受第2组剂量的TMZ和第3组剂量的PTX。在另一组荷实体艾氏癌(SEC)小鼠中研究TMZ对PTX抗肿瘤活性的影响,该组小鼠分组情况与上述分组相似。TMZ减轻了瑞士小鼠中与PTX相关的触觉异常性疼痛、热痛觉减退、麻木和精细运动失调。本研究结果表明,TMZ的神经保护作用可归因于对TLR4/p38信号通路的抑制,这还包括基质金属蛋白酶-9(MMP9)蛋白水平以及促炎细胞因子白细胞介素-1β(IL-1β)的降低,同时维持抗炎细胞因子白细胞介素-10(IL-10)的水平。此外,本研究首次证明PTX降低了神经元中Klotho蛋白的水平,并表明TMZ联合治疗可对其进行调节。另外,本研究表明TMZ既不改变SEC的生长,也不影响PTX的抗肿瘤活性。总之,我们认为:(1)神经组织中Klotho蛋白的抑制及TLR4/p38信号通路的上调可能与PIPN有关;(2)TMZ通过调节TLR4/p38和Klotho蛋白表达减轻PIPN,且不干扰其抗肿瘤活性。